Milestone Pharmaceuticals announced a workforce reduction of about 20%, expected to be completed by the first quarter of 2027. The company says broader efficiency measures are intended to lower operating expenses by roughly 30%.
CFO Amit Hasija resigned effective November 13, 2026. VP of Finance Anthony Krick is serving as principal financial and accounting officer while the company searches for a replacement CFO.
CMO David Bharucha’s role ended November 12 as part of the restructuring; he is transitioning to a consulting/advisory role with the company.
The cuts aim to extend Milestone’s cash runway into late 2028 as it develops its heart-rhythm treatment CARDAMYST and advances clinical work. The company expects about $2 million in one-time restructuring-related costs.
CARDAMYST generated $1 million in Q3 sales, up 73% from the prior quarter. The company reported a $25.8 million quarterly net loss, underscoring the financial pressure behind the cost reductions.
Sources:
Milestone Q3: CFO and CMO Out, 30% Cost Cut, RTW PIK Extended to 2029
Milestone Posts $80.5M Nine-Month Loss, Cuts 20% of Staff to Extend Runway
Milestone cuts 20% of staff as Cardamyst sales hit $1M in Q3
Milestone is cutting 20% of its staff, with its CMO and CFO exiting, as heart drug ...
Milestone (MIST) Q3 2026 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (MIST) Q3 FY2026 ...
Layoff Tracker: Cellectis may cut 70% of workforce
Milestone Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
UPDATE: Milestone Pharmaceuticals (MIST) - The Company Marked Down Its Own Launch
Milestone Pharmaceuticals Inc. (MIST) — SEC | Wiseek
Milestone Cuts 30% of Costs, Extends Cash Runway to Late 2028 as CFO and CMO Exit
Milestone Pharmaceuticals plans roughly 20% job cuts
Milestone expects ~30% expense cuts, runway into late 2028 | MIST …
Milestone Posts Wider-Than-Expected Q3 Revenue, Narrows Loss to 18 Cents a Share
Milestone Receives Nasdaq Bid-Price Deficiency Notice, 180 Days to April 21, 2027